Creative Proteomics Cytokine Unveils Disease Cytokine Assays for Disease Diagnosis
Cytokine division belongs to Creative Proteomics, which specializes in providing cytokine research and analysis services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Creative Proteomics Cytokine recently announced Disease Cytokine Assays to help researchers obtain higher quality scientific research data.
Cytokines, including interleukins, interferons, tumor necrosis factors, and chemokines, can play key pro- and anti-inflammatory roles in vivo through a variety of biochemical pathways and interactions. Compared with other types of testing methods for infections and inflammatory diseases, the detection of cytokines has the advantages of non-invasiveness and low cost, and has been used as an inflammatory marker for the diagnosis of various diseases.
“Creative Proteomics has multiple cytokine detection platforms such as multiplex Luminex, flow cytometry, and ELISA. We will choose the right technology combination according to your project, meet your various needs, and help researchers obtain higher quality scientific research data,” stated Creative Proteomics’s Senior Scientist.
Biomarkers are indicators that can determine the occurrence, development, and prognosis of diseases, and play an important role in early diagnosis, disease prevention, drug target confirmation, and drug response. Biomarker detection can provide insight into the mechanism of action or resistance of new drugs in disease models.
Creative Proteomics can provide detection services for cytokines and biomarkers for the majority of pharmaceutical R&D personnel. Its Cytokine division has complete infrastructure and advanced equipment, and has the Luminex cytokine detection platform that can perform multi-form cytokine and biomarker detection. Whether it is the early screening of a large number of candidate cytokines and biomarkers, or the large-scale validation of specific factors and biomarkers, Creative Proteomics can find suitable technology platforms and services to meet R&D needs.
“We mainly use the Luminex cytokine detection platform, which uses fluorescently encoded microspheres with specific antibodies to different target molecules. The different microspheres can be combined freely to a certain extent, so that up to 100 analytes can be tested multiple times simultaneously in a single experiment,” stated Creative Proteomics’s Product Manager.
“Creative Proteomics also utilizes flow cytometry (FACS analysis) and enzyme-linked immunosorbent assay (ELISA) to perform simultaneous quantitative detection of disease cytokines with higher sensitivity and a wider detection range,” he added.
The multi-cytokines detectable by Creative Proteomics include but are not limited to the following:
- Cancer Cytokines Assay
- Cytokine Storm Assays
- Autoimmune Disease Cytokines Assay
- Inflammation Cytokines Assay
- Rheumatoid Arthritis Cytokines Assay
- Atopic Dermatitis Cytokines Assay
- Osteoporosis Cytokines Assay
- Apoptosis Cytokines Assay
- Diabetes Cytokines Assay
- lmmunomodulatory Cytokines Assay
- Hypertension Cytokines Assay
- Systemic Lupus Erythematosus Cytokines Assay
- Cardiovascular Disease Biomarker Assay
About Creative Proteomics
Creative Proteomics is an innovative contract research organization that focuses on using advanced equipment platforms and optimized detection technology to help researchers around the world reduce time and costs. The company has a proprietary laboratory information management system to strengthen laboratory quality monitoring and quality management to ensure the efficiency and security of customer data.